Isavuconazonium Dosage
Medically reviewed by Drugs.com. Last updated on Jan 28, 2025.
Applies to the following strengths: 186 mg; 372 mg; 74.5 mg
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Aspergillosis - Invasive
Loading Dose: 372 mg IV or orally every 8 hours for 6 doses (48 hours)
Maintenance Dose: 372 mg IV or orally once a day
Comments:
- Isavuconazonium sulfate is the prodrug of isavuconazole; 372 mg of isavuconazonium sulfate is equivalent to 200 mg of isavuconazole.
- Maintenance doses should be started 12 to 24 hours after the last loading dose.
Uses: For the treatment of invasive aspergillosis and invasive mucormycosis
Usual Adult Dose for Mucormycosis - Invasive
Loading Dose: 372 mg IV or orally every 8 hours for 6 doses (48 hours)
Maintenance Dose: 372 mg IV or orally once a day
Comments:
- Isavuconazonium sulfate is the prodrug of isavuconazole; 372 mg of isavuconazonium sulfate is equivalent to 200 mg of isavuconazole.
- Maintenance doses should be started 12 to 24 hours after the last loading dose.
Uses: For the treatment of invasive aspergillosis and invasive mucormycosis
Renal Dose Adjustments
Mild, moderate, or severe renal dysfunction: No adjustment recommended.
Liver Dose Adjustments
Mild to moderate liver dysfunction (Child-Pugh A and B): No adjustment recommended.
Severe liver dysfunction (Child-Pugh C): Data not available
Comments:
- This drug should be used in patients with severe liver dysfunction only if the benefits outweigh the risks.
Precautions
CONTRAINDICATIONS:
- Known hypersensitivity to the active component
- Coadministration with strong CYP450 3A4 inhibitors (e.g., ketoconazole, high-dose ritonavir [400 mg every 12 hours])
- Coadministration with strong CYP450 3A4 inducers (e.g., rifampin, carbamazepine, long-acting barbiturates, St. John's wort)
- Familial short QT syndrome
Safety and efficacy have not been established in patients younger than 18 years.
Consult WARNINGS section for additional precautions.
Dialysis
ESRD: No adjustment recommended.
Other Comments
Administration advice:
- Administer IV formulation via an infusion set with an in-line filter (pore size 0.2 to 1.2 micron).
- Infuse the IV formulation over a minimum of 1 hour in 250 mL of compatible diluent (to reduce risk for infusion-related reactions); do not administer as IV bolus injection.
- Do not infuse with any other IV drugs.
- Flush IV lines with 0.9% sodium chloride injection, USP or 5% dextrose injection, USP before and after infusion.
- Avoid unnecessary vibration or vigorous shaking of the diluted IV solution; do not use a pneumatic transport system.
- May switch between IV and oral formulations (bioequivalent); no loading dose needed when switching between formulations.
- Swallow capsules whole; do not chew, crush, dissolve, or open capsules.
- Administer capsules with or without food.
- For nasogastric (NG) tube administration, administer the reconstituted injection solution within 1 hour of reconstitution.
- To administer, connect the syringe containing the reconstituted solution to the NG tube to deliver the dose.
- After administering the dose, administer 3 rinses (5 mL each) with water to the NG tube.
Storage requirements:
- Capsules: Store at 20C to 25C (68F to 77F) in the original bottle to protect from moisture; excursion permitted to 15C to 30C (59F to 86F).
- Injection (unreconstituted vials): Store at 2C to 8C (36F to 46F) in refrigerator.
- Injection (reconstituted solution): Should use immediately
- For IV administration: May be stored below 25C up to 1 hour before preparation of the patient IV infusion solution
- For NG tube administration: Should administer within 1 hour of reconstitution
- Injection (diluted IV infusion solution): Complete iv infusion within 6 hours of dilution at room temperature (20C to 25C [68F to 77F]); if this is not possible, refrigerate (2C to 8C [36F to 46F]) the infusion solution immediately after dilution and complete the IV infusion within 24 hours; do not freeze.
Reconstitution/preparation techniques:
- For IV administration of the injection formulation: Requires reconstitution and then dilution before infusion
- For NG tube administration of the injection formulation: Requires reconstitution before administration
- The manufacturer product information should be consulted.
IV compatibility:
- Compatible diluents: 0.9% sodium chloride injection, USP; 5% dextrose injection, USP
General:
- Specimens for fungal culture and other relevant laboratory studies (including histopathology) should be obtained before therapy to isolate and identify causative organisms; therapy may be started before results are known, but once available, antifungal therapy should be adjusted accordingly.
Monitoring:
- General: For drug-related side effects in patients with severe liver dysfunction
- Hepatic: Liver-related laboratory tests (at the start of and during therapy); for more severe hepatic injury in patients with abnormal liver-related laboratory tests (during therapy)
Patient advice:
- Read the US FDA-approved patient labeling (Patient Information).
More about isavuconazonium
- Check interactions
- Compare alternatives
- Reviews (2)
- Side effects
- During pregnancy
- Drug class: azole antifungals
- En español
Patient resources
- Isavuconazonium oral/injection drug information
- Isavuconazonium (Intravenous) (Advanced Reading)
- Isavuconazonium (Oral) (Advanced Reading)
- Isavuconazonium Sulfate Capsules
Other brands
Professional resources
Other brands
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.